Standard BioTools Inc. (LAB) Revenue History
Annual and quarterly revenue from 2006 to present
LAB Revenue Over Time (2006–2025)
LAB Revenue Growth History
13 of 19 years with positive growth- FY2006 revenue growth
- N/A
- FY2007 revenue growth
- +13.7%
- FY2008 revenue growth
- +111.0%
- FY2009 revenue growth
- +65.6%
- FY2010 revenue growth
- +32.1%
- FY2011 revenue growth
- +27.7%
- FY2012 revenue growth
- +22.1%
- FY2013 revenue growth
- +36.0%
- FY2014 revenue growth
- +63.6%
- FY2015 revenue growth
- -1.5%
- FY2016 revenue growth
- -8.9%
- FY2017 revenue growth
- -2.4%
- FY2018 revenue growth
- +10.8%
- FY2019 revenue growth
- +3.8%
- FY2020 revenue growth
- +17.8%
- FY2021 revenue growth
- -5.5%
- FY2022 revenue growth
- -25.0%
- FY2023 revenue growth
- +8.6%
- FY2024 revenue growth
- +64.0%
- FY2025 revenue growth
- -51.1%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $21.1M | -48.2% |
| Q4 2025 | $3.2M | -93.1% |
| Q3 2025 | $19.6M | -56.5% |
| Q2 2025 | $21.8M | -3.2% |
| Q1 2025 | $40.8M | -10.4% |
| Q4 2024 | $46.7M | +65.7% |
| Q3 2024 | $45.0M | +77.3% |
| Q2 2024 | $22.5M | -18.7% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
LAB's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
LAB Revenue Analysis (2006–2025)
Current Revenue & Growth
As of June 23, 2026, Standard BioTools Inc. (LAB) generated trailing twelve-month (TTM) revenue of $65.7 million, reflecting significant decline in growth of -48.2% year-over-year. The most recent quarter (Q1 2026) recorded $21.1 million in revenue, up 556.3% sequentially.
Historical Growth Trajectory
LAB's 5-year compound annual growth rate (CAGR) stands at -9.2%, indicating revenue contraction over this period. The 3-year CAGR of -4.5% exceeds the 5-year average, indicating an acceleration in the most recent period. Standard BioTools Inc.'s highest annual revenue of $174.4 million was recorded in 2024.
Revenue by Segment
LAB's revenue is primarily driven by Product (42%), Consumables (25%), and Instruments (17%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including AZTA (+1.8% YoY), NTRA (+36.6% YoY), and PACB (+5.0% YoY) — LAB has underperformed the peer group in revenue growth. Compare LAB vs AZTA →
LAB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LABCurrent | $66M | -48.2% | -9.2% | -109.3% | |
 AZTA | $594M | +1.8% | +8.9% | -1.9% | |
 NTRA | $2.3B | +36.6% | +42.6% | -13.4% | |
 PACB | $160M | +5.0% | +15.2% | -348.5% | |
 SEER | $16M | -0.9% | +89.7% | -486.7% | |
 CDNA | $380M | +19.2% | +14.6% | -5.5% |
LAB Historical Revenue Data (2006–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $85.3M | -51.1% | $42.5M | 49.9% | $-93,305,000 | -109.3% |
| 2024 | $174.4M | +64.0% | $84.3M | 48.3% | $-175,236,000 | -100.5% |
| 2023 | $106.3M | +8.6% | $50.5M | 47.4% | $-76,600,000 | -72.0% |
| 2022 | $97.9M | -25.0% | $37.1M | 37.8% | $-116,205,000 | -118.6% |
| 2021 | $130.6M | -5.5% | $69.4M | 53.1% | $-67,459,000 | -51.7% |
| 2020 | $138.1M | +17.8% | $83.3M | 60.3% | $-51,036,000 | -36.9% |
| 2019 | $117.2M | +3.8% | $64.3M | 54.8% | $-51,839,000 | -44.2% |
| 2018 | $113.0M | +10.8% | $61.6M | 54.6% | $-48,164,000 | -42.6% |
| 2017 | $101.9M | -2.4% | $52.0M | 51.0% | $-58,360,000 | -57.3% |
| 2016 | $104.4M | -8.9% | $58.4M | 55.9% | $-73,190,000 | -70.1% |
| 2015 | $114.7M | -1.5% | $68.1M | 59.4% | $-50,155,000 | -43.7% |
| 2014 | $116.5M | +63.6% | $73.6M | 63.2% | $-51,836,000 | -44.5% |
| 2013 | $71.2M | +36.0% | $51.1M | 71.8% | $-17,950,000 | -25.2% |
| 2012 | $52.3M | +22.1% | $37.0M | 70.7% | $-18,071,000 | -34.5% |
| 2011 | $42.9M | +27.7% | $29.7M | 69.2% | $-18,566,000 | -43.3% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LAB — Frequently Asked Questions
Quick answers to the most common questions about buying LAB stock.
Is LAB's revenue growth accelerating or slowing?
LAB revenue is declining -48.2% year-over-year. TTM revenue fell to $66M, contrasting with the 5-year CAGR of -9.2%. The reversal reflects either macro headwinds or company-specific challenges.
What is LAB's revenue history from 2006 to 2026?
Standard BioTools Inc. (LAB) revenue history spans 2006 to 2026. TTM revenue as of 2026 is $66M, growing at -48.2% YoY. The 5-year CAGR is -9.2%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is LAB's long-term revenue growth rate (CAGR)?
Standard BioTools Inc.'s 5-year revenue CAGR of -9.2% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -48.2% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for LAB.
Why does LAB's quarterly revenue fluctuate?
LAB quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Standard BioTools Inc.'s revenue data from 2006 to 2026 shows full historical quarterly detail on this page.
How is LAB's revenue distributed by segment?
LAB reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does LAB's revenue compare to industry peers?
Standard BioTools Inc. (LAB) with TTM revenue of $66M and -48.2% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.